CoChat
Sign Up
Cited by 7Diabetes Treatment and ManagementMetabolism, Diabetes, and CancerDiabetes Management and Research

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Cancer related safety with SGLT2-i and GLP1-RAs: Should we worry?

Gallo, M., Monami, M., Ragni, A., Renzelli, V.·2023·Diabetes Research and Clinical Practice
DOI 10.1016/j.diabres.2023.110624
Open this paper in CoChat — free account

Overview

Integrity signals

Registry

Crossref · 10.1016/j.diabres.2023.110624

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 34

  1. Shi, 2021, SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials, Front Public Health, 9
  2. García, 2021, SGLT2 Inhibitors and Bladder Cancer: Analysis of Cases Reported in the European Pharmacovigilance Database, The Journal of Clinical Pharmacology, 61, 187, 10.1002/jcph.1722 · DOI
  3. Tang, 2017, SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials, Diabetologia, 60, 1862, 10.1007/s00125-017-4370-8 · DOI · Paper page
  4. Tang, 2018, Meta-analysis of the association between sodium-glucose co-transporter-2 inhibitors and risk of skin cancer among patients with type 2 diabetes, Diabetes Obes Metab, 20, 2919, 10.1111/dom.13474 · DOI
  5. Pelletier, 2020, The association of sodium-glucose cotransporter 2 inhibitors with cancer: An overview of quantitative systematic reviews, Endocrinol DiabetesMetab, 3
  6. Abrahami, 2022, Sodium-Glucose Cotransporter 2 Inhibitors and the Short-term Risk of Bladder Cancer: An International Multisite Cohort Study, Diabetes Care, 45, 2907, 10.2337/dc22-1174 · DOI
  7. Luo, 2023, Sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-small cell lung cancer survival, Br J Cancer, 10.1038/s41416-023-02177-2 · DOI
  8. Yamamoto, 2021, Sodium-glucose cotransporter 2 inhibitor canagliflozin attenuates lung cancer cell proliferation in vitro, Diabetol Int, 12, 389, 10.1007/s13340-021-00494-6 · DOI
  9. Ding, 2023, Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling, J Clin Investig, 133
  10. Hendryx, 2022, Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis, PLoS One, 17, e0274519, 10.1371/journal.pone.0274519 · DOI
  11. Nakachi, 2022, Impact of anti-diabetic sodium-glucose cotransporter 2 inhibitors on tumor growth of intractable hematological malignancy in humans, Biomed Pharmacother, 149, 10.1016/j.biopha.2022.112864 · DOI
  12. Zhou, 2020, Sodium-glucose co-transporter-2 (SGLT-2) inhibition reduces glucose uptake to induce breast cancer cell growth arrest through AMPK/mTOR pathway, Biomed Pharmacother, 132, 10.1016/j.biopha.2020.110821 · DOI
  13. Nalla, 2023, Empagliflozin mediated miR-128-3p upregulation promotes differentiation of hypoxic cancer stem-like cells in breast cancer, Eur J Pharmacol, 943, 10.1016/j.ejphar.2023.175565 · DOI
  14. Komatsu, 2020, SGLT2 inhibitor ipragliflozin attenuates breast cancer cell proliferation, Endocr J, 67, 99, 10.1507/endocrj.EJ19-0428 · DOI
  15. Xie, 2020, An SGLT2 inhibitor modulates SHH expression by activating AMPK to inhibit the migration and induce the apoptosis of cervical carcinoma cells, Cancer Lett, 495, 200, 10.1016/j.canlet.2020.09.005 · DOI
  16. Wu, 2022, SGLT2 inhibitor activates the STING/IRF3/IFN-β pathway and induces immune infiltration in osteosarcoma, Cell Death Dis, 13, 523, 10.1038/s41419-022-04980-w · DOI
  17. Wang, 2022, SGLT2 inhibition restrains thyroid cancer growth via G1/S phase transition arrest and apoptosis mediated by DNA damage response signaling pathways, Cancer CellInt, 22, 74
  18. Qiang, 2022, SGLT-2 as a potential target in pancreatic cancer: the preliminary clue from The Cancer Genome Atlas data, J Gastrointest Oncol, 13, 2539, 10.21037/jgo-22-900 · DOI
  19. Ren, 2021, SGLT2 promotes pancreatic cancer progression by activating the Hippo signaling pathway via the hnRNPK-YAP1 axis, Cancer Lett, 519, 277, 10.1016/j.canlet.2021.07.035 · DOI
  20. Bardaweel, 2022, Exploring the Role of Sodium-Glucose Cotransporter as a New Target for Cancer Therapy, J Pharm Pharm Sci, 25, 253, 10.18433/jpps32879 · DOI
  21. Lau, 2021, Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment – A Review, Rev Endocr Metab Disord, 22, 1121, 10.1007/s11154-021-09675-9 · DOI
  22. Chiang, 2023, Impact of sodium-glucose cotransporter-2 inhibitors on heart failure and mortality in patients with cancer, Heart, 109, 470, 10.1136/heartjnl-2022-321545 · DOI
  23. Chang, 2021, Dapagliflozin suppresses ER stress and protects doxorubicin-induced cardiotoxicity in breast cancer patients, Arch Toxicol, 95, 659, 10.1007/s00204-020-02951-8 · DOI
  24. Gongora, 2022, Sodium-Glucose Co-Transporter-2 Inhibitors and Cardiac Outcomes Among Patients Treated With Anthracyclines, JACC Heart Fail, 10, 559, 10.1016/j.jchf.2022.03.006 · DOI
  25. Benedetti, 2022, Effects of novel SGLT2 inhibitors on cancer incidence in hyperglycemic patients: a meta-analysis of randomized clinical trials, Pharmacol Res, 175, 10.1016/j.phrs.2021.106039 · DOI
  26. Alves, 2012, A meta-analysis of serious adverse events reported with exenatide and liraglutide: Acute pancreatitis and cancer, Diabetes Res Clin Pract, 98, 271, 10.1016/j.diabres.2012.09.008 · DOI · Paper page
  27. Song, 2017, Expression of GLP-1 receptor and CD26 in human thyroid C-cells: The association of thyroid C-cell tumorigenesis with incretin-based medicine, Oncol Lett, 13, 2684, 10.3892/ol.2017.5752 · DOI
  28. Acharya, 2003, Thyroid neoplasms after therapeutic radiation for malignancies during childhood or adolescence, Cancer, 97, 2397, 10.1002/cncr.11362 · DOI
  29. Clement, 2018, Cancer Treat Rev, 63, 28, 10.1016/j.ctrv.2017.11.005 · DOI
  30. Schuster-Bruce, 2022, A Comparison of the Burden of Thyroid Cancer Among the European Union 15+ Countries, 1990–2019, JAMA Otolaryngology-Head & Neck Surgery, 148, 350, 10.1001/jamaoto.2021.4549 · DOI
  31. Barrea, 2021, Nutritional status and follicular-derived thyroid cancer: An update, Crit Rev Food Sci Nutr, 61, 25, 10.1080/10408398.2020.1714542 · DOI
  32. Nixon, 2016, The impact of family history on non-medullary thyroid cancer, European Journal of Surgical Oncology (EJSO), 42, 1455, 10.1016/j.ejso.2016.08.006 · DOI
  33. Durante, 2020, Clinically Silent Thyroid Cancers: Drop Those Needles and Scalpels!, J Clin Endocrinol Metab, 105, e889, 10.1210/clinem/dgz129 · DOI
  34. Haugen, 2016, 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer, Thyroid, 26, 1, 10.1089/thy.2015.0020 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Gallo, M., Monami, M., Ragni, A., & Renzelli, V.
Affiliations
  • Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare Arrigo (IT)
  • Azienda Ospedaliero-Universitaria Careggi (IT)
Corresponding author
Gallo, M.
ORCID
Venue
Diabetes Research and Clinical Practice
Publisher
Elsevier BV
Published
2023-04
Volume
198
Pages
110624
ISSN
0168-8227 (ISSN-L)
DOI
10.1016/j.diabres.2023.110624
OpenAlex
W4323660200
Cited by
7
References
6
Citations by year
2026: 1 · 2024: 5 · 2023: 1
FWCI
1.43
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Diabetes Research and Clinical Practice (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Keywords
SGLT2 inhibitors, GLP-1 receptor agonists, cancer risk, type 2 diabetes, bladder cancer, drug safety, cardioprotection, chronic kidney disease, heart failure
MeSH terms
Glucagon-Like Peptide-1 Receptor, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Neoplasms, Sodium-Glucose Transporter 2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review